Rare Disease Genetic Testing Market

Rare Disease Genetic Testing Market Analysis and Forecast by Fact.MR

• The global rare disease genetic testing market is estimated at US$ 1.2 billion in 2025, forecast to expand at a CAGR of 15.3% to reach US$ 5.7 billion by 2036.
• Rare disease genetic testing encompasses next generation sequencing panels, whole exome sequencing, chromosomal microarray analysis, and PCR based tests used to identify genetic causes of rare disorders.
• Demand is expanding as sequencing costs decline, national genomic medicine programs scale, and clinical pathways integrate genetic testing into diagnostic workflows for patients with undiagnosed conditions.

Summary of Rare Disease Genetic Testing Market

• Market Snapshot
  • In 2025, the global Rare Disease Genetic Testing Market was valued at approximately USD 1.2 billion.
  • The market is estimated to reach USD 1.4 billion in 2026 and is projected to attain USD 5.7 billion by 2036.
  • The rare disease genetic testing market is likely to expand at a CAGR of 15.3% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 4.4 billion between 2026 and 2036.
  • Sequencing Based Tests account for 48% of product type share in 2026.
  • China (16.6%) and Brazil (15.3%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Declining sequencing costs are making whole exome and genome sequencing economically viable for broader clinical application in rare disease diagnosis.
  • National genomic medicine programs in the USA, UK, France, China, and Saudi Arabia are scaling rare disease genetic testing as part of public health infrastructure.
  • Growing number of targeted therapies approved for specific genetic conditions is creating clinical urgency to identify actionable genetic diagnoses.
  • Expanding institutional procurement and healthcare infrastructure development across emerging economies is increasing demand.
  • Product innovation and format diversification are broadening market access across clinical and non clinical channels.
• Product and Segment View
  • Sequencing Based Tests account for 48% of the product type segment in 2026, supported by established clinical use and procurement patterns.
  • Diagnostic Testing accounts for 52% of the application segment in 2026.
  • Key segmentation includes:
    • Product Type: Sequencing Based Tests, Whole Exome Sequencing, Targeted Gene Panels, Chromosomal Microarray Analysis, PCR Based Tests
    • Application: Diagnostic Testing, Carrier Screening, Newborn Screening, Prenatal Testing
    • End Use: Diagnostic Laboratories, Hospitals, Research Institutes
    • Technology: Next Generation Sequencing Technology, Microarray Technology, Polymerase Chain Reaction Technology, Bioinformatics and Data Analysis
    • Formulation: Reagent Kits, Sample Preparation Kits, Assay Kits, Control and Calibration Materials
    • Distribution Channel: Direct Sales, Distributors, Online Sales
  • These systems enable:
    • Comprehensive genomic analysis for identifying causative variants in patients with undiagnosed rare disorders
    • Carrier screening and prenatal testing for heritable genetic conditions in family planning settings
    • Newborn screening expansion through genomic platforms enabling early intervention in treatable rare diseases
• Geography and Competitive Outlook
  • China leads growth at 16.6%, supported by government genomic medicine investment, domestic sequencing platform development, and expanding hospital based genetic testing adoption.
  • Latin America shows strong momentum with Brazil at 15.3%, driven by rare disease awareness programs and growing laboratory testing infrastructure.
  • North America remains the largest market with the USA at 14.9%, driven by payer coverage expansion, genomic medicine integration, and established reference laboratory networks.
  • Key companies include Quest Diagnostics Incorporated, Centogene N.V., Invitae Corporation, 3billion Inc., ARUP Laboratories, and Eurofins Scientific SE, Strand Life Sciences Pvt. Ltd., Ambry Genetics, PerkinElmer Inc. (now Revvity, Inc.), Realm IDX Inc..
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The rare disease genetic testing market is at an inflection point where falling sequencing costs, expanding clinical evidence, and government program investment are converging to create sustained double digit growth. The diagnostic odyssey for rare disease patients is being shortened from years to weeks as genomic testing moves from research into clinical care pathways. Companies that combine sequencing capability with bioinformatics interpretation, clinical decision support, and payer engagement are positioned to capture the highest value growth.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Declining sequencing costs are making whole exome and genome sequencing economically viable for broader clinical application in rare disease diagnosis.
• National genomic medicine programs in the USA, UK, France, China, and Saudi Arabia are scaling rare disease genetic testing as part of public health infrastructure.
• Growing number of targeted therapies approved for specific genetic conditions is creating clinical urgency to identify actionable genetic diagnoses.

Key Market Constraints

• Variant interpretation complexity and the high rate of variants of uncertain significance reduce the diagnostic yield of genetic testing for many rare conditions.
• Reimbursement coverage inconsistency across payers and geographies limits market access for advanced sequencing based tests.
• Genetic counseling workforce shortages constrain the capacity to deliver pre and post test counseling at scale.

Key Opportunity Areas

• Genomic newborn screening programs are creating large scale testing volumes with potential to identify treatable rare diseases before symptom onset.
• AI and machine learning tools for variant classification and phenotype matching are improving diagnostic yield and clinical utility.
• Pharmacogenomic testing integration is linking rare disease diagnosis with treatment selection, increasing the clinical and commercial value of genetic testing.

Segment-wise Analysis of the Rare Disease Genetic Testing Market

• Sequencing Based Tests hold 48% of the respective segment in 2026.
• Diagnostic Testing hold 52% of the respective segment in 2026.
• Next Generation Sequencing Technology hold 50% of the respective segment in 2026.

Which Product Type Segment Leads the Rare Disease Genetic Testing Market?

Sequencing based tests account for 48% of the product type segment in 2026. Whole exome sequencing and targeted gene panels are the primary testing modalities, with clinical utility established across hundreds of rare disease indications. Falling sequencing costs and improving bioinformatics interpretation are expanding clinical adoption beyond academic genetics centers.

The segment benefits from the breadth of diagnostic coverage that sequencing provides compared to single gene or microarray approaches. Whole exome sequencing can identify variants across approximately 20,000 genes in a single test, making it the preferred first tier diagnostic approach for patients with undiagnosed conditions.

Which Application Segment Leads the Rare Disease Genetic Testing Market?

Diagnostic testing accounts for 52% of the application segment in 2026. Genetic testing for patients with suspected rare diseases represents the largest demand category, with clinical geneticists, neurologists, and pediatricians ordering tests to identify causative variants and guide treatment decisions.

The segment benefits from growing clinical awareness that genetic testing can end diagnostic uncertainty for patients who have undergone years of inconclusive investigations. Expanding insurance coverage and clinical guideline endorsement are increasing test ordering rates across both academic and community healthcare settings.

Which Technology Segment Leads the Rare Disease Genetic Testing Market?

Next generation sequencing technology accounts for 50% of the technology segment in 2026. Illumina and other sequencing platforms provide the hardware and chemistry foundation for the majority of rare disease genetic tests, with throughput and cost improvements continuing to expand clinical accessibility.

The segment is strengthened by platform versatility, where the same sequencing infrastructure supports targeted panels, whole exome, and whole genome testing configurations. Bioinformatics pipeline development and cloud based analysis platforms are complementing hardware capability to improve overall diagnostic utility.

Which Product Trend is Shaping the Next Phase of Growth in the Rare Disease Genetic Testing Market?

Genomic newborn screening is emerging as the most significant growth opportunity in the market. National programs in the UK, Australia, and parts of the USA are piloting whole genome or whole exome sequencing of newborns to identify treatable rare diseases before symptoms develop. These programs have the potential to generate millions of new tests annually if scaled to national populations.

The shift toward newborn genomic screening reflects growing evidence that early identification of treatable genetic conditions improves clinical outcomes and reduces long term healthcare costs. As program results validate clinical utility and cost effectiveness, genomic newborn screening is expected to transition from pilot programs into routine public health infrastructure, creating a large scale recurring demand source for sequencing reagents, bioinformatics services, and genetic counseling.

Regional Outlook Across Key Markets

• China leads growth at 16.6%, supported by government genomic medicine investment, domestic sequencing platform development, and expanding hospital based genetic testing adoption.
• Latin America shows strong momentum with Brazil at 15.3%, driven by rare disease awareness programs and growing laboratory testing infrastructure.
• North America remains the largest market with the USA at 14.9%, driven by payer coverage expansion, genomic medicine integration, and established reference laboratory networks.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Rare Disease Genetic Testing in the United States

The U.S. rare disease genetic testing market is projected to grow at a CAGR of 14.9% through 2036. Demand is supported by payer coverage expansion, reference laboratory networks, and genomic medicine integration.

• Payer coverage expansion for whole exome sequencing is increasing test volumes.
• Reference laboratory networks provide broad geographic access to advanced testing.
• Newborn screening pilots are creating potential for large scale testing adoption.

Rare Disease Genetic Testing Demand Trends in China

The China rare disease genetic testing market is projected to grow at a CAGR of 16.6% through 2036. Growth reflects government genomic medicine investment and domestic sequencing platform development.

• Government genomic medicine programs support institutional testing adoption.
• Domestic sequencing platform development improves pricing accessibility.
• Hospital based genetic testing departments are expanding across major medical centers.

Japan Rare Disease Genetic Testing Market Growth Assessment

The Japan rare disease genetic testing market is projected to grow at a CAGR of 15.1% through 2036. Demand is shaped by healthcare system investment and clinical genetics infrastructure development.

• Healthcare system investment supports genomic testing integration.
• Clinical genetics programs enable structured rare disease diagnostic pathways.
• Regulatory frameworks support clinical adoption of sequencing based diagnostics.

France Rare Disease Genetic Testing Market Demand Analysis

The France rare disease genetic testing market is projected to grow at a CAGR of 14.3% through 2036. Demand is supported by the national genomic medicine program and reference center networks.

• National Plan for Rare Diseases supports systematic genetic testing.
• Reference center networks provide specialized diagnostic expertise.
• Genomic medicine program investment sustains laboratory testing capacity.

Brazil Rare Disease Genetic Testing Market Opportunity Outlook

The Brazil rare disease genetic testing market is projected to grow at a CAGR of 15.3% through 2036. Growth is supported by rare disease awareness programs and expanding laboratory infrastructure.

• Rare disease awareness programs increase diagnostic testing utilization.
• Laboratory infrastructure development supports genomic testing adoption.
• Public health initiatives support access to genetic diagnosis for underserved populations.

Competitive Benchmarking and Company Positioning

Rare Disease Genetic Testing Market Analysis By Company

• Quest Diagnostics Incorporated holds a leading position with approximately 21% share, supported by a broad product portfolio and established institutional relationships.
• Centogene N.V., Invitae Corporation, 3billion Inc. participate meaningfully across specific categories and regional channels.
• Competition is shaped by product differentiation, regulatory approvals, institutional procurement, and geographic distribution.

The competitive landscape is moderately fragmented. Quest Diagnostics Incorporated leads through portfolio breadth and regulatory approvals. Centogene N.V., Invitae Corporation, 3billion Inc. maintain relevance across specific niches. Strategic priorities include expanding product portfolios, strengthening distribution, and investing in next generation development.

Key Companies in the Rare Disease Genetic Testing Market

• Quest Diagnostics Incorporated, Centogene N.V., Invitae Corporation, 3billion Inc. are among the leading players globally.
• ARUP Laboratories, Eurofins Scientific SE, Strand Life Sciences Pvt. Ltd., Ambry Genetics, PerkinElmer Inc. (now Revvity, Inc.), Realm IDX Inc. hold positions across specific segments and regional markets.

Recent Industry Developments

• Quest Diagnostics Incorporated : Testing Expansion / Rare Disease Panel Updates (2025)
  • Quest Diagnostics continued to expand its rare disease genetic testing menu with updated sequencing panels covering newly identified disease genes, supporting clinicians with broader diagnostic coverage for patients with undiagnosed conditions.
• Revvity, Inc. (formerly PerkinElmer) : Newborn Screening / Genomic Platform Development (2025)
  • Revvity advanced its genomic newborn screening platform development, supporting pilot programs evaluating whole genome sequencing integration into routine newborn screening workflows.
• Centogene N.V. : Bioinformatics / Variant Interpretation Enhancement (2025)
  • Centogene continued to enhance its proprietary rare disease variant database and bioinformatics platform, improving diagnostic yield for clinicians ordering rare disease genetic tests through its global laboratory network.

Leading Companies Shaping the Rare Disease Genetic Testing Market

• Quest Diagnostics Incorporated
• Centogene N.V.
• Invitae Corporation
• 3billion Inc.
• ARUP Laboratories
• Eurofins Scientific SE
• Strand Life Sciences Pvt. Ltd.
• Ambry Genetics
• PerkinElmer Inc. (now Revvity, Inc.)
• Realm IDX Inc.

Sources and Research References

• Quest Diagnostics Incorporated. Rare disease genetic testing portfolio updates.
• Revvity, Inc. Newborn screening platform development updates.
• National Institutes of Health. Rare disease genomic research and Undiagnosed Diseases Program.
• Genomics England. National genomic medicine program data and rare disease testing outcomes.
• Primary interviews with clinical geneticists, laboratory directors, bioinformatics specialists, and payer representatives.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the rare disease genetic testing market?
• How fast is the market expected to grow between 2026 and 2036?
• Which product type leads the market by 2026?
• Which application segment accounts for the highest demand?
• What factors are driving demand globally?
• How is genomic newborn screening influencing the market?
• Why is China the fastest growing market?
• Which countries show the fastest growth through 2036?
• Who are the key companies?
• How does Fact.MR estimate the forecast?

Rare Disease Genetic Testing Market Definition

The rare disease genetic testing market covers next generation sequencing based tests including whole exome sequencing and targeted gene panels, chromosomal microarray analysis, and PCR based assays used to identify genetic causes of rare disorders. It includes reagent kits, sample preparation materials, bioinformatics analysis platforms, and variant interpretation services used across diagnostic laboratories, hospitals, and research institutes for diagnostic testing, carrier screening, newborn screening, and prenatal testing applications.

Rare Disease Genetic Testing Market Inclusions

• Global and regional market size and forecasts for 2026 to 2036 across product type, application, end use, technology, formulation, distribution channel, and region.
• Regional demand analysis based on rare disease prevalence, genomic medicine program investment, sequencing adoption, and laboratory infrastructure.
• Pricing analysis across targeted panel, exome, genome, and microarray testing categories.
• Competitive landscape including testing platforms, laboratory networks, and bioinformatics capabilities.

Rare Disease Genetic Testing Market Exclusions

• General purpose sequencing equipment and consumables not specifically configured for rare disease testing.
• Common disease genetic risk scoring and polygenic risk assessment products.
• Direct to consumer ancestry and wellness genetic testing services.
• Pharmacogenomic testing products not linked to rare disease diagnosis.

Rare Disease Genetic Testing Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 100+ secondary sources and benchmarks 50+ company product portfolios.
• Market sizing covers 30+ countries through a demand side model, supported by top down validation.
• Key inputs include disease incidence data, institutional procurement patterns, regulatory frameworks, and product pricing trends.
• The model cross checks demand with shipment volumes, pricing trends, channel mix, and product launch timelines.
• Primary validation includes 25+ interviews across manufacturers, distributors, healthcare providers, and institutional procurement officers.
• Final estimates go through supply validation, trade flow checks, and sensitivity testing.